Propanc Biopharma, Inc. PPCB NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • AU • USD

SharesGrow Score

28/100

0/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Propanc Biopharma, Inc. (PPCB) generated $-405.17K in operating cash flow for fiscal year 2025. After capital expenditures of $0.00, free cash flow was $-405.17K.

Cash conversion ratio was 0.01x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
INCOME (?/100) — Cash conversion ratio was 0.01x suggests some earnings are non-cash items

Overall SharesGrow Score: 25/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

28/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

Proven by this page

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Propanc Biopharma, Inc. Cash Flow History

Metric	TTM	FY2025	FY2024	FY2023	FY2022
Operating Cash Flow	$-3.1M	$-405.17K	$-935.12K	$-1.11M	$-1.44M
Capital Expenditure	$-4.76K	$0.00	$-2.00	$1.00	$4.00
Free Cash Flow	$-3.1M	$-405.17K	$-935.12K	$-1.11M	$-1.44M